US Stock Market Move | Treatment of genetic bone diseases in the research drug clinical trial failed, Ultragenyx Pharmaceutical (RARE.US) plunges over 42% in pre-market trading.
As of the filing, the stock is down over 42%, trading at $19.69.
Before Monday's US stock market opening, Ultragenyx Pharmaceutical (RARE.US) stock price plummeted. As of press time, the stock has fallen more than 42% to $19.69. On the news front, the company announced that its investigational drug for treating a specific genetic bone disease did not meet the primary efficacy endpoint in late-stage clinical trials.
Related Articles
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
